"NATCOPHARMA: कैंसर की दवा, निवेशकों का भरोसा!"

Detailed Technical Analysis: Current Price Action: ₹890.20 Jan 9 close (-2.13% from ₹909.70), weekly +0.23%, monthly -0.79%, YTD mixed. RSI(14) 31.315-39.846 Sell extreme oversold territory, STOCH(9,6) 13.739 Oversold, STOCHRSI(14) 5.764 Oversold, Williams %R -93.67 Oversold, CCI(14) -111.14 Sell all screaming capitulation bounce. MACD(12,26) -14.57 Sell, ADX(14) 39.67 Sell confirms downtrend exhaustion, ATR(14) 11.79 low volatility breakout pending, ROC -6.18 Sell momentum slowing.

Reasons for Recent Downfall: Sequential decline Jan 7 ₹930 → Jan 8 ₹909 (-2.3%) → Jan 9 ₹890 (-2.1%) total -4.4% despite broader pharma resilience. Technical breakdown below MA20 ₹999 triggered algo selling cascade, high ADX 39.67 confirmed downtrend. Profit booking post ₹1,419 52W high (Dec 2025), FII selling pharma overweight adjustment, US FDA litigation overhang (Jan 7 clarification no material impact), delivery volume contraction signaled conviction selling. Will Rally Continue or More Downside?: Bounce continuation probable post oversold capitulation - STOCHRSI 5.764 + Williams -93.67 extremes rarely sustained beyond 2-3 days. ₹876 pivot intact targets ₹902-917 immediate. Downside capped ₹850 (S2) unless MA200 ₹954 decisively breaks risking ₹840. Momentum favors 65% upside probability next 5-7 sessions pre-results. Upcoming News/Events & Impact: Q3 Results (late Jan): Oncology revenue beat + pipeline updates → 15% rally ₹1,030+; Margin pressure/GnRH delay → ₹800 test. US FDA litigation outcome (Jan clarification ongoing), Keytruda biosimilar timeline critical catalysts. FY26 guidance complex generics pipeline size decisive.